News and Trends 1 Dec 2015
How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies
Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation…